Compare Twist Bioscience Corp (TWST) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wayfair Inc — how do they compare? Twist Bioscience Corp trades at $163.28 (market cap $10.08B), while Wayfair Inc trades at $105.67 (market cap $14.40B). The key difference: Wayfair Inc is the larger of the two by market cap, and Twist Bioscience Corp is more actively traded (4,229,037 versus 2,102,856). Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Wayfair Inc for 8 Days on average.
| TWST | W | |
|---|---|---|
Market Cap | $10.08B | $14.40B |
Volume | 4,229,037 | 2,102,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $205.00 | $119.05 |
52-Week Low | $25.45 | $57.40 |
Typical Hold Time | 27 Days | 8 Days |
Enterprise Value | $10.01B | $16.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Wayfair (W) trades at $105.70, up 1.18% today, with a bullish technical signal and strong analyst support. The stock shows positive earnings surprises in recent quarters, though it remains unprofitable with a net income margin of -2.49%. Revenue growth is modest, and the company maintains a solid gross profit margin of 30.05%. Recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook is cautiously optimistic with a consensus price target of $114.13, implying upside potential. Key risks include persistent losses, high debt-to-asset ratio, and competitive pressures. Investor sentiment is positive, but profitability challenges and macroeconomic headwinds warrant careful monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
